Post highlights CorMedix (CRMD) as a potential high-growth opportunity similar to Moderna's recent performance, projecting 1x-2x returns. Key risks include biotech volatility, clinical trial outcomes, regulatory approval uncertainty, and the speculative nature of comparing to past winners.

Post highlights CorMedix (CRMD) as a potential growth opportunity similar to Moderna's past performance, suggesting a 1-2x upside setup. Key risks include biotech volatility, clinical trial outcomes, regulatory approval uncertainty, and the speculative nature of comparing to past outlier performers.